COVID-19 and Heart Failure

Loading

COVID-19 restrictions are easing. What does that mean for heart failure patients?

Although the coronavirus is still a major health threat, restrictions are easing across the nation. That leaves many people— including heart failure patients — wondering if it’s safe to go out in public and get back to a normal routine. 

The most important thing to remember is that people with heart disease, including heart failure, are at risk of getting much sicker or even dying if they get COVID-19.  So if you have a history of heart disease or have a risk factor for heart disease or stroke, stay informed and stay cautious. 

Learn more here.

Loading

SGLT2 Inhibitor Adds Years of Life to Patients With Heart Failure

Loading

“Patients with heart failure with reduced ejection fraction (HFrEF) may increase their lifespan if they take the SGLT2 inhibitor dapagliflozin (Farxiga) over the long term, a statistical modeling study showed.

Mean event-free survival was an estimated 8.3 years in a patient with HFrEF who started dapagliflozin at age 65. As a similar patient on standard therapy alone would only be expected to live free from heart failure events for another 6.2 years, this represented an event-free survival time gain of 2.1 years (P=0.002).”

Learn more, here.

Loading